Table 1 Gleason 7 patients in the PROMIS cohort and 30 selected patients for in-depth analysis.

From: A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists

 

UCH—PROMIS cohort (4 + 3 or ≥ 6 mm MCCL)

p value (3 + 4 vs 4 + 3)

Selected 30 patients

p value (3 + 4 vs 4 + 3)

Gleason score

3 + 4

4 + 3

 

3 + 4

4 + 3

 

n = 67 (78%)

n = 18 (22%)

 

n = 15 (50%)

n = 15 (50%)

 

Age (years)

63 (43–77)

64 (48–79)

0.44*

62 (50–72)

65 (48–79)

0.30*

Prostate volume (cc)

38.34 (16–83)

38.18 (26–55)

0.65**

34 (21–62)

38 (26–55)

0.11**

Presenting PSA (ng/dL)

7.46 (1.30–13)

10.76 (5.7–15)

< 0.0001*

7.60 (4.9–10.1)

10.74 (6.2–15)

0.0005*

PSA density (PSAd)

0.22 (0.06–0.59)

0.29 (0.11–0.53)

0.002**

0.24 (0.10–0.38)

0.29 (0.11–0.53)

0.14*

Likert 2

1 (1.4%)

0

 

0

0

 

Likert 3

8 (11.9%)

3 (16.6%)

 

1 (6.6%)

0

 

Likert 4

21 (31.3%)

3 (16.6%)

 

6 (40%)

4 (26.6%)

 

Likert 5

5 (7.46%)

12 (66.6%)

 

8 (53.3%)

11 (73.3%)

 

Likert NA

4 (5.87%)

0

 

0

1 (6.6%)

 
  1. Table comparing the Gleason 7 patients from University College London (UCH) within the PROMIS study. UCH PROMIS cohort is on the left, selected patients on the right. Number of patients per group by Gleason score in each cohort as n = , percentage in parenthesis. Mean value for age, prostate volume, presenting PSA and PSA density, with range in parenthesis. Age is denoted in years, prostate volume in cubic centimetres (cc), PSA in ng/dL and PSA density calculated as PSA/prostate volume. Likert scores are presented as number of patients and percentage in parenthesis, Likert NA when no Likert score was given. *p-value obtained using an unpaired t-test, **if using Mann–Whitney test.
Back to article page